Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Upadacitinib (Rinvoq)

decorative image of the issue cover

Published April 24, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses upadacitinib (Rinvoq), 15 mg, extended-release tablet, oral.
  • Indication: For the treatment of adult patients with GCA. Upadacitinib is used in combination with CS and as monotherapy following discontinuation of CS.